Explore the cutting-edge advancements in immunotherapy delivery with our deep dive into the latest injectable chitosan hydrogel, a game-changer in targeted treatment applications.
– by James
Note that James is a diligent GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
Characterization of an Injectable Chitosan Hydrogel for the Tunable, Localized Delivery of Immunotherapeutics.
Mantooth et al., ACS Biomater Sci Eng 2024
DOI: 10.1021/acsbiomaterials.3c01580
What’s New: The development of a novel chitosan-based hydrogel, XCSgel, designed for localized delivery of immunotherapeutics in tumor treatment.
Importance: This hydrogel addresses the challenge of retaining therapeutics at the tumor site after intratumoral injection, which is crucial for reducing systemic side effects and enhancing treatment efficacy.
Contribution to Literature: XCSgel is characterized by its shear-thinning and self-healing properties, which help maintain its presence within the tumor. It has been shown to be biocompatible and capable of releasing therapeutics in a controlled, charge-dependent manner over an extended period.
– Nuclear Magnetic Resonance (NMR): Used to determine the chemical structure of XCSgel.
– Cryo-Scanning Electron Microscopy: Provided images of the hydrogel’s network.
– Rheology: Confirmed XCSgel’s shear-thinning and self-healing behavior.
– Biocompatibility: Assessed through in vitro and in vivo studies, indicating non-toxicity and only transient, mild-to-moderate inflammation.
– Release Studies: Demonstrated prolonged, charge-dependent release of immunotherapeutics.
XCSgel’s unique properties make it a promising vehicle for localized cancer immunotherapy, potentially improving the clinical management of tumors.